Winton Group’s Maze Therapeutics MAZE Stock Holding History

Winton Group’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,487	Closed	-$376K	–	1152
2025 Q3	$376K	Buy	+14,487	New	+$245K	0.01%	603

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Winton Group's MAZE Position: Q4 2025 in Review

Winton Group sold out of Maze Therapeutics (MAZE) in Q4 2025, closing a stake of 14,487 shares — an estimated $376K sold.

Winton Group first reported a position in MAZE in Q3 2025 and held it in 1 quarter. The position peaked at $376K in Q3 2025. 143 funds tracked by Wall St. Rank hold MAZE as of Q4 2025.

Winton Group reported no remaining Maze Therapeutics position as of Q4 2025 after selling out during the quarter.
Winton Group sold 14,487 Maze Therapeutics shares in Q4 2025, an estimated $376K.
Winton Group first reported a position in Maze Therapeutics in Q3 2025 and held it in 1 quarter.
Winton Group's Maze Therapeutics position peaked at $376K in Q3 2025.
143 funds tracked by Wall St. Rank held Maze Therapeutics as of Q4 2025.

Based on Winton Group's 13F filing for Q4 2025, filed 11 Feb 2026.